Loading...
Loading...
PHXM| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.7M |
| Operating I/L | 12.6M |
| Other Income/Expense | 2.0M |
| Interest Income | -0.8M |
| Pretax | 14.6M |
| Income Tax Expense | 3.7M |
| Net Income/Loss | 10.9M |
PHAXIAM Therapeutics S.A. is a biopharmaceutical company with a focus on developing treatments for resistant bacterial infections. Its flagship product, eryaspase, is in advanced clinical development for the treatment of second-line pancreatic cancer, triple-negative breast cancer, and second-line acute lymphoblastic leukemia. Additionally, the company is developing a portfolio of phages targeting dangerous bacteria, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa, which are responsible for the majority of resistant hospital-acquired infections. Through the development and commercialization of these innovative treatments, PHAXIAM Therapeutics S.A. generates revenue from the sale of its pharmaceutical products and potential licensing agreements.
